Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1986 Jan;63(1):1–7.

Interleukin 2 augmentation of the defective natural killer cell activity in patients with primary Sjögren's syndrome.

B K Pedersen, P Oxholm, R Manthorpe, V Andersen
PMCID: PMC1577338  PMID: 3485480

Abstract

Natural Killer (NK) cell activity against K562 target cells was measured in 21 female patients with primary Sjögren's syndrome (primary SS) and in 20 female normal controls matched for age. The in vitro effect of alpha-interferon (IF) and interleukin 2 (IL-2) on NK cell activity was examined and the percentage of large granular lymphocytes (LGL) in blood was measured. Median baseline NK cell activity in primary SS was 15.4% versus 24.4% in the controls (P less than 0.05). Median IF-enhanced NK cell activity in the SS group was 35.5% versus 49.6% in the controls (P less than 0.02). IL-2-enhanced NK cell activity was 35.5% versus 37.6% in the controls (n.s.) The proportion of LGL did not differ in the two groups. Median LGL/lymphocytes was 4.0% in the primary SS patients versus 4.5% in the controls (n.s.). We conclude that the defective NK cell activity in patients with primary SS is functional, as the number of LGL is normal. Further the NK cell activity off SS was restored by IL-2.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman A., Theofilopoulos A. N., Weiner R., Katz D. H., Dixon F. J. Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2. J Exp Med. 1981 Sep 1;154(3):791–808. doi: 10.1084/jem.154.3.791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cantell K., Hirvonen S. Large-scale production of human leukocyte interferon containing 10(8) units per ml. J Gen Virol. 1978 Jun;39(3):541–543. doi: 10.1099/0022-1317-39-3-541. [DOI] [PubMed] [Google Scholar]
  3. Carpén O., Virtanen I., Saksela E. The cytotoxic activity of human natural killer cells requires an intact secretory apparatus. Cell Immunol. 1981 Feb;58(1):97–106. doi: 10.1016/0008-8749(81)90152-0. [DOI] [PubMed] [Google Scholar]
  4. Domzig W., Stadler B. M., Herberman R. B. Interleukin 2 dependence of human natural killer (NK) cell activity. J Immunol. 1983 Apr;130(4):1970–1973. [PubMed] [Google Scholar]
  5. Farrar J. J., Benjamin W. R., Hilfiker M. L., Howard M., Farrar W. L., Fuller-Farrar J. The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses. Immunol Rev. 1982;63:129–166. doi: 10.1111/j.1600-065x.1982.tb00414.x. [DOI] [PubMed] [Google Scholar]
  6. Gerstoft J., Malchow-Møller A., Bygbjerg I., Dickmeiss E., Enk C., Halberg P., Haahr S., Jacobsen M., Jensen K., Mejer J. Severe acquired immunodeficiency in European homosexual men. Br Med J (Clin Res Ed) 1982 Jul 3;285(6334):17–19. doi: 10.1136/bmj.285.6334.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  8. Gillis S., Smith K. A. Long term culture of tumour-specific cytotoxic T cells. Nature. 1977 Jul 14;268(5616):154–156. doi: 10.1038/268154a0. [DOI] [PubMed] [Google Scholar]
  9. Goto M., Tanimoto K., Horiuchi Y. Natural cell mediated cytotoxicity in systemic lupus erythematosus: suppression by antilymphocyte antibody. Arthritis Rheum. 1980 Nov;23(11):1274–1281. doi: 10.1002/art.1780231108. [DOI] [PubMed] [Google Scholar]
  10. Henney C. S., Kuribayashi K., Kern D. E., Gillis S. Interleukin-2 augments natural killer cell activity. Nature. 1981 May 28;291(5813):335–338. doi: 10.1038/291335a0. [DOI] [PubMed] [Google Scholar]
  11. Ichikawa Y., Yoshida M., Takaya M., Uchiyama M., Shimizu H., Arimori S. Circulating natural killer cells in Sjögren's syndrome. Arthritis Rheum. 1985 Feb;28(2):182–187. doi: 10.1002/art.1780280213. [DOI] [PubMed] [Google Scholar]
  12. Kasahara T., Djeu J. Y., Dougherty S. F., Oppenheim J. J. Capacity of human large granular lymphocytes (LGL) to produce multiple lymphokines: interleukin 2, interferon, and colony stimulating factor. J Immunol. 1983 Nov;131(5):2379–2385. [PubMed] [Google Scholar]
  13. Manthorpe R., Frost-Larsen K., Isager H., Prause J. U. Sjögren's syndrome. A review with emphasis on immunological features. Allergy. 1981 Apr;36(3):139–153. doi: 10.1111/j.1398-9995.1981.tb01829.x. [DOI] [PubMed] [Google Scholar]
  14. Mazumder A., Rosenberg S. A. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med. 1984 Feb 1;159(2):495–507. doi: 10.1084/jem.159.2.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mier J. W., Gallo R. C. Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media. Proc Natl Acad Sci U S A. 1980 Oct;77(10):6134–6138. doi: 10.1073/pnas.77.10.6134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Minato N., Takeda A., Kano S., Takaku F. Studies of the function of natural killer-interferon system in patients with Sjögren syndrome. J Clin Invest. 1982 Mar;69(3):581–588. doi: 10.1172/JCI110484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Miyasaka N., Nakamura T., Russell I. J., Talal N. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol. 1984 Apr;31(1):109–117. doi: 10.1016/0090-1229(84)90195-8. [DOI] [PubMed] [Google Scholar]
  18. Miyasaka N., Seaman W., Bakshi A., Sauvezie B., Strand V., Pope R., Talal N. Natural killing activity in Sjögren's syndrome. An analysis of defective mechanisms. Arthritis Rheum. 1983 Aug;26(8):954–960. doi: 10.1002/art.1780260803. [DOI] [PubMed] [Google Scholar]
  19. Ortaldo J. R., Herberman R. B. Heterogeneity of natural killer cells. Annu Rev Immunol. 1984;2:359–394. doi: 10.1146/annurev.iy.02.040184.002043. [DOI] [PubMed] [Google Scholar]
  20. Pedersen B. K., Beyer J. M., Rasmussen A., Klarlund K., Hørslev-Petersen K., Pedersen B. N., Helin P. Azathioprine as single drug in the treatment of rheumatoid arthritis induces complete suppression of natural killer cell activity. Acta Pathol Microbiol Immunol Scand C. 1984 Aug;92(4):221–225. doi: 10.1111/j.1699-0463.1984.tb00078.x. [DOI] [PubMed] [Google Scholar]
  21. Pedersen B. K., Beyer J. M., Rasmussen A., Klarlund K., Pedersen B. N., Helin P. Methylprednisolone pulse therapy induced fall in natural killer cell activity in rheumatoid arthritis. Acta Pathol Microbiol Immunol Scand C. 1984 Oct;92(5):319–323. doi: 10.1111/j.1699-0463.1984.tb00094.x. [DOI] [PubMed] [Google Scholar]
  22. Pedersen B., Norrild B., Krebs H. J. The effect of monensin on the antibody-dependent cell-mediated killing. Cell Immunol. 1982 Sep 1;72(1):208–214. doi: 10.1016/0008-8749(82)90299-4. [DOI] [PubMed] [Google Scholar]
  23. Reddy M. M., Pinyavat N., Grieco M. H. Interleukin 2 augmentation of natural killer cell activity in homosexual men with acquired immune deficiency syndrome. Infect Immun. 1984 May;44(2):339–343. doi: 10.1128/iai.44.2.339-343.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rey A., Klein B., Zagury D., Thierry C., Serrou B. Diminished interleukin-2 activity production in cancer patients bearing solid tumors and its relationship with natural killer cells. Immunol Lett. 1983 Mar;6(3):175–178. doi: 10.1016/0165-2478(83)90101-3. [DOI] [PubMed] [Google Scholar]
  25. Strannegård O., Hermodsson S., Westberg G. Interferon and natural killer cells in systemic lupus erythematosus. Clin Exp Immunol. 1982 Nov;50(2):246–252. [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES